A randomized clinical trial for evaluating effects of activated donor liver mononuclear cells inoculation on liver transplantation recipients with hepatitis C (HCV).

A randomized clinical trial for evaluating effects of activated donor liver mononuclear cells inoculation on liver transplantation recipients with hepatitis C (HCV). - A randomized clinical trial for evaluating effects of Liver mononuclear cells on HCV liver transplantation recipients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000538

Enrollment

Registered

2007-01-01

Start date

2007-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver transplantation recipients with HCV

Interventions

Participated patients will be randomly divided into two groups. One is cell therapy group and the other is untreated group. Patients in cell therapy group are injected activated donor liver mononuclea

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are expected to be recipients for living-donor liver transplantation Patients who have submitted a written informed consent Patients with hepatitis C

Exclusion criteria

Exclusion criteria: Symptomatic infectious disease Fluminant hepatitis ABO incompatible transplantation Retransplantation Decision as ineligible by principal investigators

Design outcomes

Primary

Measure	Time frame
5-year survival rate, and SVR	—

Secondary

Measure	Time frame
Adverse events, Postoperative infectious complication rate, Median overall survival	—

Countries

Japan

Contacts

Public ContactMasahiro Ohira

Graduate school of biomedical sciences, Hiroshima university Department of surgery, division of frontier medical science, programs for biomedical research

mohira@hiroshima-u.ac.jp082-257-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026